SCHEMBL238537

SCHEMBL238537

COC(=O)c1cc(C(=O)c2ccc(Br)cn2)ccc1C(=O)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LTC4S Q16873 10/20 0.51
KDM4E B2RXH2 3/20 0.43
HPGD P15428 2/20 0.43
LMNA P02545 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MAPK1 P28482 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ABCG2 Q9UNQ0 1/20 0.42
AKR1C3 P42330 1/20 0.42
HSD17B10 Q99714 1/20 0.41
ALDH1A1 P00352 1/20 0.41
KMT2A Q03164 1/20 0.41
POLB P06746 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2458815 0.89 LTC4S (0.50) LTC4SKDM4EHPGDSMN1; SMN2MAPK1
SCHEMBL237749 0.83 HSD17B10 (0.44) LTC4SKDM4EHPGDLMNACYP1A2
SCHEMBL236631 0.82 MAPK1 (0.44) LTC4SKDM4ELMNASMN1; SMN2MAPK1
SCHEMBL235942 0.81 MAPT (0.59) KDM4EHPGDLMNACYP1A2CYP2D6
SCHEMBL256768 0.79 ALDH1A1 (0.63) KDM4EHPGDSMN1; SMN2L3MBTL1AKR1C3
SCHEMBL236561 0.79 LTC4S (0.73) LTC4S
SCHEMBL236562 0.77 LTC4S (0.49) LTC4SLMNA
SCHEMBL27586077 0.77 TSHR (0.55) KDM4EHPGDLMNACYP1A2CYP2D6
SCHEMBL28560378 0.74 AKR1C3 (0.64) KDM4EHPGDLMNASMN1; SMN2MAPK1
SCHEMBL5260070 0.73 RAB9A (0.65) LTC4SKDM4EHPGDLMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130035358-A1 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors BIOLIPOX AB (SE) 2013-02-07 US disclosed
EP-2545036-A1 BIS AROMATIC COMPOUNDS FOR USE AS LTC4 SYNTHASE INHIBITORS Biolipox AB (SE) 2013-01-16 EP disclosed
US-20120004244-A1 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors BIOLIPOX AB (SW) 2012-01-05 US disclosed
WO-2011110824-A1 BIS AROMATIC COMPOUNDS FOR USE AS LTC4 SYNTHASE INHIBITORS BIOLIPOX AB (SE) 2011-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004244-A1 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors LTC4S, LTB4R2, LTB4R LTC4S 1/4885KDM4E 2809/4885HPGD 174/4885
US-20130035358-A1 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors LTC4S, LTB4R2, LTB4R LTC4S 1/4885KDM4E 2809/4885HPGD 174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.